… inhibitors as OATP1B1/OATP1B3 … transporters to study in vitro and in vivo, in vitro
methodologies, and decision trees on key transporters as to when to conduct in vivo drug interaction …

… Olaparib showed inhibition of the hepatic drug uptake transporters OATP1B1 (IC 50 values
of 20.3 μM and 27.1 μM) and OCT1 (IC 50 37.9 μM), but limited inhibition of OATP1B3 (25% …

… of the International Transporter Consortium. Predictions for AZX … OATP1B1-mediated DDI
in vivo and that a clinical interaction study is warranted to confirm whether AZX is an OATP1B1 …

… hepatic uptake transporters. Early assessment of OATP1B1/1B3-mediated drug–drug interactions
(… For OATP1B1 transporter, such an external test has so far only been performed in the …

… no risk of clinically relevant drug–drug interactions with substrates of BCRP, OATP1B1,
or OATP1B3. The potential for relevant inhibition of these transporters suggested by in vitro …

… special occasions such as drug–drug interactions (DDI) and genetic polymorphisms of …
OATP1B1, 1B3 and 2B1 by directly measuring the relative expression levels of these transporters …

… drug transporters generally exhibit broad substrate specificity, and it is frequently observed
that drugs interacting with one transporter will most likely interact … inhibition of OATP1B1 ([I] in …

… Hepatocytes highly express some uptake transporters (such as OATP1B1, OATP1B3,
OATP2B1, and OCT1), mediating uptake of the substrates (eg, statins and metformin) into …

… organic cation transporters (OCTs) and organic anion transporters (… drugs and
transporter-mediated drug-drug interactions and we especially focus on the uptake transporters …

… drug–drug interaction between SUs and rosuvastatin, which was one representative of
lipidaemia-modulating drugs and was the common substrate of OATP1B1 … against transporters …